EMERGENT BIOSOLUTIONS INC. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets
EMERGENT BIOSOLUTIONS INC. (EBS) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets of 3.50% for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets · last filed 2024-03-08
- EMERGENT BIOSOLUTIONS INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2022 was 3.50%, a 16.67% increase from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2021 was 3.00%, a 0.00% change from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2020 was 3.00%, a 0.00% change from fiscal 2019.
- EMERGENT BIOSOLUTIONS INC. defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2019 was 3.00%, a 0.00% change from fiscal 2018.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 12 month |
|---|---|
| 2022-12-31 | 3.50% 10-K · filed 2024-03-08 |
| 2021-12-31 | 3.00% 10-K/A · filed 2023-12-11 |
| 2020-12-31 | 3.00% 10-K · filed 2022-02-25 |
| 2019-12-31 | 3.00% 10-K · filed 2021-02-19 |
| 2018-12-31 | 3.00% 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |